Mulligan to get $25m from Jazz Pharma's public offering

Irish pharma executive Seamus Mulligan is in line for a $25 million windfall from Jazz Pharmaceuticals after it announced an underwritten public offering of some its shares.

10th March, 2013

Irish pharma executive Seamus Mulligan is in line for a $25 million windfall from Jazz Pharmaceuticals after the Dublin-based company announced an underwritten public offering of some its shares.

Jazz, which is listed on New York's Nasdaq exchange, said 5,375,000 of its shares were being put on the market, 425,000 of which are owned by Mulligan. His shares are valued at around $25 million.

The transaction will see his shareholding in the company fall from 4.2 per cent to...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Newsround: What Thursday’s papers say